Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.42 |
| ▸ | PTGFR | P43088 | 3/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1174440 | 1.00 | NPSR1 (0.49) | NPSR1EGFRMIFPTGER3PTGER2 | |
| SCHEMBL10865615 | 0.85 | NPSR1 (0.47) | NPSR1EGFRMIFPTGER3PTGER2 | |
| SCHEMBL11791653 | 0.85 | ATG4B (0.43) | NPSR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11791639 | 0.85 | ATG4B (0.43) | NPSR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11791982 | 0.84 | ATG4B (0.45) | — | |
| SCHEMBL11791976 | 0.84 | ATG4B (0.45) | — | |
| SCHEMBL3685251 | 0.83 | EGFR (0.53) | EGFRMIFPTGER3PTGER2PTGER4 | |
| SCHEMBL9447849 | 0.83 | MIF (0.60) | EGFRMIFPTGER3PTGER2PTGER4 | |
| SCHEMBL10350184 | 0.83 | MIF (0.60) | EGFRMIFPTGER3PTGER2PTGER4 | |
| SCHEMBL3685249 | 0.83 | EGFR (0.53) | EGFRMIFPTGER3PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746512-A | Composition for forming cured film, alignment material, and phase difference material | 日产化学株式会社 | 2022-07-12 | — | — | CN | disclosed |
| CN-106980233-B | Cured film-forming composition, alignment material, and phase difference material | 日产化学工业株式会社 | 2021-07-13 | — | — | CN | disclosed |
| CN-112384834-A | Cured film, alignment material, and phase difference material | 日产化学株式会社 | 2021-02-19 | — | — | CN | disclosed |
| CN-107463066-B | Cured film-forming composition, alignment material, and phase difference material | 日产化学工业株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-105283512-B | Composition for forming cured film, alignment material, and phase difference material | 日产化学工业株式会社 | 2018-12-11 | — | — | CN | disclosed |
| US-9823400-B2 | Cured film formation composition, orientation material, and retardation material | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| CN-104603650-B | It is orientated manufacture method, orientation material, the manufacture method of phase difference material and the phase difference material of material | 日产化学工业株式会社 | 2017-06-06 | — | — | CN | disclosed |
| US-9598547-B2 | Cured-film formation composition, orientation material, and retardation material | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-03-21 | — | — | US | disclosed |
| CN-104204120-B | Cured film formation composition, oriented material and phase difference material | 日产化学工业株式会社 | 2017-03-08 | — | — | CN | disclosed |
| US-9405154-B2 | Method for manufacturing orientation material, orientation material, method for manufacturing retardation material, and retardation material | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20040171626-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| WO-2004065367-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
| EP-1265903-B1 | THIEPINO[3,2-B]DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS | ORTHO MCNEIL PHARM INC (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1411928-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-04-28 | — | — | EP | disclosed |
| US-20030236251-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-25 | — | — | US | disclosed |
| WO-2003007945-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-01-30 | — | — | WO | disclosed |
| EP-1265903-A1 | THIEPINO[3,2-B]DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6420383-B1 | CALCIUM CHANNEL BLOCKERS, HYPERSENSITIVITY, ALLERGY, ASTHMA, BRONCHOSPASM, DYSMENORRHEA, ESOPHAGEAL SPASM, GLAUCOMA, PREMATURE LABOR, URINARY TRACT DISORDERS, GASTROINTESTINAL MOTILITY DISORDERS AND CARDIOVASCULAR DISORDERS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-07-16 | — | — | US | disclosed |
| WO-2001070748-A1 | THIEPINO [3,2-b] DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-4101543-A | DYES FOR CELLULOSE ACETATES, AROMATIC POLYESTERS OR POLYAMIDES | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236251-A1 | Viral polymerase inhibitors | POLR2H, CTDSP1, POLR2E | NPSR1 3559/4885EGFR 916/4885MIF 3192/4885 |
| US-20040171626-A1 | Viral polymerase inhibitors | POLM, MED1, POLR2H | NPSR1 4058/4885EGFR 3677/4885MIF 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.